Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

NCT05262517 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
126
Enrollment
INDUSTRY
Sponsor class

Stopped Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Conditions

Interventions

Sponsor

Pfizer